249420.KO Il Dong Pharmaceutical Co Ltd
- Market cap
- KRW 409B
- P/E
- 8.9x
- P/B
- 1.49x
- ROE
- 10.8%
- Dividend yield
- 0.01%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 249420.KO undervalued?
Graham number249420.KO trades 23.2% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Il Dong Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Il Dong Pharmaceutical Co Ltd yet.
Il Dong Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Il Dong Pharmaceutical Co Ltd
Ildong Pharmaceutical Co., Ltd. develops, manufactures, and sells pharmaceutical products in South Korea. The company offers active lactic acid bacterial and anti-diarrheal agents, antibiotics, antifungal and antiviral products, anti-cancer, antineoplastic agents, and NSAIDs and analgesics, as well as vitamins, minerals, and nutrients; and drugs for blood circulation, cardiovascular and central nervous system, dental, endocrine and metabolic system, gastrointestinal system, …
Full company profileIl Dong Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Il Dong Pharmaceutical Co Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 201B | 461B | 504B | 517B | 562B | 560B | 638B | 601B | 615B | 567B | 580B |
| Gross Profit | 97.3B | 226B | 255B | 232B | 238B | 219B | 236B | 214B | 233B | 220B | 231B |
| Operating Income | 14.8B | 25.4B | 28.3B | -1.37B | 6.63B | -54.4B | -73.3B | -53.4B | 13.1B | 19.5B | 26.1B |
| EBITDA | - | 42.6B | 43.6B | 10.5B | 22.6B | -101B | -80.5B | -51.2B | 31.2B | 66.5B | 54.6B |
| Net Income | 12.6B | 19.8B | 12.7B | -13.4B | -13.0B | -99.7B | -142B | -78.9B | -4.58B | 27.7B | 27.9B |
| EPS | - | 917 | 561 | -565 | -547 | -4,192 | -5,286 | -2,854 | -164 | 878 | 887 |
| Balance Sheet | |||||||||||
| Total Assets | 550B | 565B | 565B | 613B | 605B | 709B | 656B | 611B | 589B | 573B | 560B |
| Total Liabilities | 282B | 280B | 288B | 360B | 351B | 548B | 458B | 437B | 430B | 334B | 311B |
| Shareholders' Equity | 268B | 285B | 277B | 253B | 255B | 153B | 191B | 170B | 161B | 246B | 258B |
| Cash & Short-term Investments | 19.9B | 39.9B | 75.9B | 90.0B | 85.6B | 136B | 52.1B | 53.3B | 72.3B | 64.8B | 53.4B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 46.0B | 73.7B | 66.6B | 41.4B | 19.4B | -11.4B | -53.5B | -36.6B | 28.3B | 19.0B | 15.6B |
| Capital Expenditure | 14.2B | 16.7B | 15.1B | 12.1B | 14.4B | 14.6B | 11.9B | 18.2B | 14.1B | 17.3B | 14.3B |
| Free Cash Flow | - | 28.9B | 45.9B | 22.0B | 160M | -31.2B | -73.1B | -54.8B | 14.2B | 1.62B | 1.23B |
| Ratios | |||||||||||
| ROE | 4.7% | 7.0% | 4.6% | -5.3% | -5.1% | -65.2% | -74.0% | -46.6% | -2.8% | 11.2% | 10.8% |
| ROA | 2.3% | 3.5% | 2.3% | -2.2% | -2.2% | -14.1% | -21.6% | -12.9% | -0.8% | 4.8% | 5.0% |
| Net Profit Margin | 6.2% | 4.3% | 2.5% | -2.6% | -2.3% | -17.8% | -22.2% | -13.1% | -0.7% | 4.9% | 4.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Il Dong Pharmaceutical Co Ltd dividends
- Dividend yield
- 0.01%
- Forward dividend
- 200.00 KRW
- Payout ratio
- 0.2%
- Ex-dividend date
- Mar 30, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 60.2M | 1.91 | 0.2% |
| 2024 | KRW 76.8M | 2.75 | - |
| 2023 | KRW 160M | 5.78 | - |
| 2022 | KRW 120M | 4.48 | - |
| 2021 | KRW 120M | 5.05 | - |
| 2020 | KRW 120M | 5.05 | - |
| 2019 | KRW 8.63B | 363 | - |
| 2018 | KRW 7.85B | 346 | 61.7% |
| 2017 | KRW 5.35B | 247 | 27.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.05:1 on Mar 5, 2020.
Who owns Il Dong Pharmaceutical Co Ltd
- Insiders 34.45%
- Institutions 4.75%
- Public & others 60.80%
- Shares outstanding 31.5M
- Free float 20.6M
Il Dong Pharmaceutical Co Ltd company profile
- Company name
- Il Dong Pharmaceutical Co Ltd
- Ticker
- 249420.KO
- ISIN
- KR7249420001
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,050
- Fiscal year end
- December
- Address
- 2, Baumoe-ro 27-gil, Seoul, South Korea, 137-130
- Phone
- 82 2 526 3114
- Website
- ildong.com
About Il Dong Pharmaceutical Co Ltd
Ildong Pharmaceutical Co., Ltd. develops, manufactures, and sells pharmaceutical products in South Korea. The company offers active lactic acid bacterial and anti-diarrheal agents, antibiotics, antifungal and antiviral products, anti-cancer, antineoplastic agents, and NSAIDs and analgesics, as well as vitamins, minerals, and nutrients; and drugs for blood circulation, cardiovascular and central nervous system, dental, endocrine and metabolic system, gastrointestinal system, respiratory system, and urogenital system applications. It also provides raw material drugs; health foods and foods; beverages; cosmetics; medical devices for scar treatment; and other drugs for treating thick wounds, osteoarthritis, periarthritis of shoulder, and artificial tears, as well as feminine cleanser products. The company was founded in 1941 and is headquartered in Seoul, South Korea.
Il Dong Pharmaceutical Co Ltd management
1- Yun Paul WoongsupCEO & Chairman